June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment
of exudative age-related macular degeneration
Author Affiliations & Notes
  • Nathalie Massamba
    PARIS, PITIE SALPETRIERE HOSPITAL , PARIS, PARIS, France
  • Footnotes
    Commercial Relationships   Nathalie Massamba, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1930. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nathalie Massamba; Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment
      of exudative age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1930.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose To evaluate the changes of outer retinal tubulations (ORTs) as seen on spectral-domain optical coherence tomography (SD OCT) in eyes with neovascular age-related macular degeneration (AMD) where treatment was switched from intravitreal ranibizumab to intravitreal aflibercept.

Methods : Prospective study of eyes diagnosed with neovascular AMD and previously treated with >6 intravitreal ranibizumab injections and switched to aflibercept, conducted at a single centre (Department of Ophthalmology at Pitié Salpetriere Hospital, Paris VI University) from January to July 2016. Before and after treatment was switched from
ranibizumab to aflibercept, SD-OCT was used to evaluate the presence of ORTs. Additional assessments in this patient group included best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA). Changes in pigment epithelium detachments (PED),presence of intraretinal cysts, and presence of subretinal fluid (SRF) were also noted.

Results : Twenty-four eyes of 24 consecutive patients (15female/nine male, mean age 70 years) diagnosed with neovascular AMD and previously treated with >6 intravitreal ranibizumab injections and switched to aflibercept were included in the analysis. After receiving aflibercept, patients were followed for a mean of 6.1 months. Prior to treatment switch, 97 % of eyes showed ORTs, while after treatment switch to aflibercept, at the end of the study period, 75 %had ORTs (p = 0.219). Changes in BCVA (LogMAR) were not statistically significant (1.16 ± 0.44 to 1.18 ± 1.06, p =0.12), however, a significant reduction in central macular thickness (CMT) (from 406 μm ± 112 to 263 μm ± 68, p = 0.001), PED (from 70.8 % to 41.7% , p = 0.016), presence of intraretinal cysts (from 83.3% to 33.3 %, p= 0.002)andSRF (from 91.7 % to 25 %, p = 0.001 ) were noted.

Conclusions : Conclusion
After switching from ranibizumab treatment to aflibercept,ORTsremained present in 75 % of eyes, and significantreductions in CMT, PED, and SRF, and presence of intraretinal cysts were observed.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×